Fresh analysis suggests that people who come off new GLP-1 drugs like Mounjaro or Wegovy can put back on lost weight at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Published data in a major health publication demonstrates that while overweight people can lose substantial amounts of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments must be cognizant of the danger of quick weight regain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery implies a reversion to original mass within about 18 months.
Comparing Therapies
The research, which looked at dozens of studies involving over 9,000 of participants, contrasted the outcomes of these new drugs with older methods.
Researchers note that people who lose weight through lifestyle changes alone usually see a less rapid weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Fast Rebound
Nutrition scientists propose the mode of action of the jabs accounts for the accelerated rebound.
These medications mimic a body's own chemical called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' results in appetite is unsuppressed, making overeating a significant risk."
An Ongoing Issue?
Medical guidelines suggest the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
Professionals say that, given the high risk of relapse, the treatment is often long-term.
This opinion is supported by pharmaceutical companies, who note that the findings "emphasize the chronic nature of excess weight," comparing it to managing conditions like diabetes.
User Accounts
People who have discontinued the jabs describe a sudden return of cravings.
"It was like something that goes on and you become extremely hungry," recalled an individual.
The struggle is exacerbated if patients have not developed lasting dietary or behavioural modifications during treatment.
Significant Adoption
Recent estimates indicate that a significant number of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Adoption is higher among females compared to males.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a magic cure and long-term success hinges on combined behavioural management.
